How to Get Vyleesi (Bremelanotide) in Montana

What Is Vyleesi and Why Was It Approved?

Bremelanotide is a melanocortin-4 receptor agonist that the FDA approved in June 2019 for HSDD in premenopausal women under the brand name Vyleesi (FDA approval label). It is the only on-demand injectable approved for this indication. The drug works by activating melanocortin receptors in the central nervous system, a pathway distinct from the daily oral option flibanserin (Kingsberg et al., 2019).

Approval rested primarily on the RECONNECT program, two replicate Phase 3 trials enrolling 1,247 premenopausal women with generalized acquired HSDD. In the pooled analysis, bremelanotide 1.75 mg produced a statistically significant improvement on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score, with a mean change of −0.7 compared to placebo. The co-primary endpoint on the Female Sexual Function Index desire domain also reached significance (Clayton et al., 2016). These results led an FDA advisory committee to vote 14-to-2 in favor of approval (FDA briefing document, 2018).

The drug carries a boxed warning about transient blood pressure increases. Systolic pressure rose by a mean of 3 mmHg in trials, resolving within 12 hours post-dose (FDA label). Patients with uncontrolled hypertension or cardiovascular disease should not use bremelanotide. Nausea is the most common adverse event, occurring in approximately 40% of patients in the RECONNECT trials, though it tends to diminish with repeated dosing (Kingsberg et al., 2019).

Montana Telehealth Prescribing Rules for Vyleesi

Montana law permits prescribing controlled and non-controlled medications via telehealth, provided the prescriber establishes an adequate provider-patient relationship. Vyleesi is not a scheduled substance, which simplifies the process. The Montana Board of Medical Examiners recognizes telehealth visits as a valid basis for prescribing when the consultation includes a clinical interview, review of medical history, and discussion of risks (Montana Board of Medical Examiners regulations).

A typical telehealth pathway looks like this. You schedule a video visit with a provider credentialed to prescribe in Montana. During the appointment, the clinician screens you for HSDD using validated instruments such as the Decreased Sexual Desire Screener (DSDS), a tool recommended by the International Society for the Study of Women's Sexual Health (Goldstein et al., 2017). If you meet criteria and have no cardiovascular contraindications, the provider can send an electronic prescription to a Montana pharmacy or a mail-order specialty pharmacy licensed to ship into the state.

Remote consultations are especially valuable for patients in rural Montana counties. Roughly 46 of Montana's 56 counties are classified as rural by the U.S. Census Bureau, and many lack a local gynecologist or sexual-medicine specialist. Telehealth collapses that distance. HealthRX's own telehealth platform connects Montana patients with licensed prescribers experienced in HSDD treatment, and most patients complete their first appointment within 3 to 5 business days of registration.

Who Can Prescribe Vyleesi in Montana?

Any Montana-licensed prescriber with authority to write non-scheduled prescriptions can prescribe bremelanotide. This includes physicians (MD and DO), nurse practitioners with full prescriptive authority under Montana's NP practice act, and physician assistants practicing under a supervisory agreement (Montana Code Annotated § 37-20-404). Montana granted full practice authority to NPs effective 2023, removing the prior collaborative-agreement requirement for experienced NPs.

In practice, the prescribers most familiar with HSDD pharmacotherapy are gynecologists, sexual-medicine specialists, and primary-care providers with continuing education in female sexual dysfunction. The Endocrine Society's clinical practice guidelines note that HSDD diagnosis should rule out relationship distress, medication-induced dysfunction, mood disorders, and hormonal contributors before initiating pharmacotherapy (Endocrine Society, 2014). A thorough differential protects against misdiagnosis, which is why the clinical interview portion of the visit matters.

Lab Work and Screening Before Starting Bremelanotide

The FDA label does not mandate specific laboratory testing before prescribing Vyleesi, but most clinicians order a baseline panel to exclude organic causes of low desire. Standard pre-prescription labs include:

• Blood pressure measurement. The label's boxed warning requires documenting that the patient does not have uncontrolled hypertension. A reading above 140/90 mmHg requires evaluation before prescribing (Whelton et al., ACC/AHA 2017).
• Thyroid panel (TSH, free T4). Hypothyroidism is a known driver of low libido and should be corrected before attributing symptoms to HSDD (Gabrielson et al., 2019).
• Serum prolactin. Hyperprolactinemia suppresses gonadotropin release and can mimic HSDD. Levels above 25 ng/mL warrant further workup (Endocrine Society guidelines).
• Total testosterone and DHEA-S. While the correlation between androgen levels and female desire is debated, the International Society for Sexual Medicine recommends measuring these to rule out adrenal insufficiency (Parish et al., 2016).
• Comprehensive metabolic panel and CBC. General health screening ensures no hepatic or renal impairment that might alter drug metabolism.

Most telehealth providers will order these labs electronically to a draw station near you. Quest Diagnostics and Labcorp both operate collection sites in Billings, Missoula, Great Falls, and Helena. Turnaround is typically 2 to 3 business days.

Pharmacy Access and 503A Compounding in Montana

Once prescribed, Vyleesi can be filled through three channels in Montana.

Specialty pharmacy (brand product). The brand autoinjector carries a wholesale acquisition cost of approximately $950 per dose. Specialty pharmacies such as CVS Specialty, Optum, and Alto ship to Montana addresses. Palatin Technologies offers a patient savings card that may reduce commercial-insurance copays (Palatin prescribing information).

503A compounding pharmacies. Montana licenses 503A pharmacies under the Montana Board of Pharmacy. These pharmacies can compound bremelanotide for individual prescriptions at a lower cost than the brand product, often $100 to $200 per dose, depending on the pharmacy's pricing. The compound is prepared as a subcutaneous injection matching the 1.75 mg dose. Under federal law (FDCA § 503A), the pharmacy must receive a valid patient-specific prescription and use bulk drug substance from an FDA-registered supplier (FDA 503A guidance).

Mail-order specialty pharmacy. For patients in remote areas, mail-order remains the most practical option. The pharmacy ships cold-chain if required and delivers directly. Montana does not impose additional restrictions on receiving non-controlled prescription medications by mail beyond standard USPS and carrier regulations.

Insurance Coverage and Prior Authorization in Montana

Montana Medicaid does not cover Vyleesi for HSDD. Commercial plans vary. Blue Cross Blue Shield of Montana and Pacific Source, two of the state's larger insurers, generally classify Vyleesi as a specialty-tier drug requiring prior authorization (CMS formulary guidance).

Prior authorization documentation typically requires:

1. A confirmed HSDD diagnosis using DSM-5 criteria (302.71 / F52.0).
2. Evidence that the patient is premenopausal with no surgical or natural menopause.
3. Documentation that the low desire is not explained by a coexisting medical condition, psychiatric disorder, relationship factor, or medication side effect.
4. A trial or clinical rationale for not using flibanserin (the oral alternative), or documentation of flibanserin failure or intolerance. Some insurers waive this step-therapy requirement.
5. A recent blood pressure reading within normal limits.

Expect the prior-authorization process to take 5 to 10 business days. If denied, Montana's insurance-appeal statutes allow external review through the Montana Commissioner of Securities and Insurance. The Utilization Review Act (MT Code Ann. § 33-32-301) mandates a response within 30 calendar days for standard appeals.

For patients paying out of pocket, the cost ranges from $150 to $300 per dose through compounding pharmacies to approximately $950 per dose for the brand autoinjector. Some patients use health savings account (HSA) or flexible spending account (FSA) funds, as Vyleesi is an FDA-approved prescription medication and qualifies as an eligible expense under IRS guidelines (IRS Publication 502).

How Long Until You Receive Vyleesi in Montana?

The timeline from first contact to first dose breaks down as follows:

• Days 1 to 3. Schedule and complete a telehealth or in-person consultation. If labs are ordered, provide samples at a local draw site.
• Days 3 to 5. Lab results return. The prescriber reviews and, if appropriate, sends the prescription electronically.
• Days 5 to 10. For brand Vyleesi through a specialty pharmacy: the pharmacy runs a benefits investigation, submits prior authorization if needed, and ships once approved. For 503A compound: the pharmacy compounds the medication (typically 1 to 3 business days) and ships or prepares for pickup.
• Days 10 to 14. Delivery. Specialty pharmacy shipping to Montana addresses, including rural routes, usually takes 2 to 4 business days via overnight or priority carriers.

Some patients complete the entire process in under 7 days if they have labs already on file and do not require prior authorization.

Transferring a Vyleesi Prescription to Montana

If you hold a valid Vyleesi prescription from another state, Montana pharmacies can accept a transferred prescription under Montana Board of Pharmacy rules. The sending pharmacy contacts the receiving pharmacy directly. Electronic transfer is standard. The prescription must be current and have remaining refills or be rewritten by the original prescriber.

If your out-of-state prescriber is not licensed in Montana and the prescription has expired, you will need a new consultation with a Montana-licensed provider. Telehealth makes this straightforward. Your prior medical records and lab results can be forwarded to the new clinician, avoiding duplicate testing.

Clinical Dosing and Self-Injection Guidance

Bremelanotide 1.75 mg is administered subcutaneously in the abdomen or thigh approximately 45 minutes before anticipated sexual activity. The autoinjector is single-use. Key dosing rules from the label:

• Do not exceed one dose in 24 hours.
• Do not exceed 8 doses per calendar month.
• If nausea occurs, it typically peaks within the first two doses and diminishes over subsequent uses. In RECONNECT, 40% of patients reported nausea, but only 1.4% discontinued for this reason (Kingsberg et al., 2019).
• Pre-treatment with an antiemetic (ondansetron 4 mg, taken 30 minutes before the injection) is an off-label strategy some clinicians recommend for the first few doses.
• Skin hyperpigmentation, particularly of the face and gums, occurred in approximately 1% of trial participants and may not fully resolve after discontinuation (FDA label).

Rotate injection sites to reduce local irritation. Store autoinjectors at room temperature (20°C to 25°C). Do not freeze. The drug should be visually inspected for particulates before use; discard if discolored.

Comparing Bremelanotide to Flibanserin for Montana Patients

Montana patients diagnosed with HSDD have two FDA-approved pharmacotherapy options. Flibanserin (Addyi) is a daily oral tablet. Bremelanotide is an as-needed injection. The choice depends on clinical factors and patient preference.

Flibanserin requires daily dosing for 4 to 8 weeks before efficacy can be assessed. It carries a REMS (Risk Evaluation and Mitigation Strategy) program due to the risk of severe hypotension and syncope when combined with alcohol (FDA REMS for Addyi). In the SNOWDROP trial, flibanserin increased sexually satisfying events by a mean of 0.5 to 1.0 per month above placebo (Katz et al., 2013).

Bremelanotide offers the advantage of on-demand dosing. No alcohol restriction applies. The main trade-off is injectable administration and the high nausea rate with initial doses. For patients who prefer not to take a daily medication or who drink alcohol, bremelanotide may be the better fit. The ISSWSH process-of-care algorithm recommends discussing both options and allowing patient preference to guide the decision (Parish et al., 2016).

Monitoring and Follow-Up After Starting Vyleesi

Follow-up visits should occur at 8 to 12 weeks after the first dose. The prescriber assesses response using validated instruments (FSFI desire domain, FSDS-DAO), checks blood pressure, and screens for adverse effects including nausea, flushing, and skin hyperpigmentation (Clayton et al., 2016).

If the patient reports no improvement after 8 doses, the FDA label recommends discontinuation. Continued use without benefit exposes the patient to unnecessary adverse-effect risk without clinical gain.

Blood pressure should be rechecked at each follow-up. Patients with borderline readings (systolic 130 to 139 mmHg) warrant closer monitoring, as bremelanotide can produce transient 3 to 6 mmHg systolic elevations (Kingsberg et al., 2019).